InMed Pharmaceuticals Inc. Announces New Formulation for Dry Age-Related Macular Degeneration Treatment

Summary

InMed Pharmaceuticals Inc. announced the selection of a new intravitreal formulation for INM-089, aimed at treating dry age-related macular degeneration (AMD). This formulation has shown successful delivery and favorable pharmacokinetic properties, suggesting a significant safety margin. This advancement addresses a key unmet medical need impacting many globally. The company’s current market cap is $2.23 million, with a year-to-date price performance of -35.83%.Tip Ranks

Impact Analysis

The event is classified at the company level, as it pertains specifically to InMed Pharmaceuticals Inc. The introduction of a new formulation for INM-089 could potentially enhance the company’s market position by addressing a significant unmet need in AMD treatment. This advancement may improve investor sentiment, particularly if clinical trials continue to show promising results. The recent release of positive pre-clinical data for another candidate, INM-901, has already had a favorable impact on the stock price, evidenced by a 22.6% increase following the announcement.Baystreet+ 2 However, despite these developments, the overall stock performance for the year remains negative, which may indicate investor caution or skepticism regarding long-term success. Investment opportunities may include increased holdings in InMed, contingent upon further positive developments and clinical trial outcomes.Press Releases+ 2